These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38316747)

  • 41. Therapeutic KRAS
    Mugarza E; van Maldegem F; Boumelha J; Moore C; Rana S; Llorian Sopena M; East P; Ambler R; Anastasiou P; Romero-Clavijo P; Valand K; Cole M; Molina-Arcas M; Downward J
    Sci Adv; 2022 Jul; 8(29):eabm8780. PubMed ID: 35857848
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
    Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
    Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EGFR Blockade Reverts Resistance to KRAS
    Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
    Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
    Khan S; Budamagunta V; Zhou D
    Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell Type-specific Adaptive Signaling Responses to KRAS
    Solanki HS; Welsh EA; Fang B; Izumi V; Darville L; Stone B; Franzese R; Chavan S; Kinose F; Imbody D; Koomen JM; Rix U; Haura EB
    Clin Cancer Res; 2021 May; 27(9):2533-2548. PubMed ID: 33619172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting KRAS in Colorectal Cancer.
    Wang C; Fakih M
    Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
    [TBL] [Abstract][Full Text] [Related]  

  • 47. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
    Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
    Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined inhibition of KRAS
    Kitai H; Choi PH; Yang YC; Boyer JA; Whaley A; Pancholi P; Thant C; Reiter J; Chen K; Markov V; Taniguchi H; Yamaguchi R; Ebi H; Evans J; Jiang J; Lee B; Wildes D; de Stanchina E; Smith JAM; Singh M; Rosen N
    Nat Commun; 2024 Jul; 15(1):6076. PubMed ID: 39025835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
    Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
    J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS
    Zhuang H; Fan J; Li M; Zhang H; Yang X; Lin L; Lu S; Wang Q; Liu Y
    Front Oncol; 2022; 12():915512. PubMed ID: 36033504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.
    Lee C; Jiang ZK; Planken S; Manzuk LK; Ortiz R; Hall M; Noorbehesht K; Ram S; Affolter T; Troche GE; Ihle NT; Johnson T; Ahn Y; Kraus M; Giddabasappa A
    Mol Cancer Ther; 2023 Jul; 22(7):891-900. PubMed ID: 37186518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
    Hofmann MH; Gmachl M; Ramharter J; Savarese F; Gerlach D; Marszalek JR; Sanderson MP; Kessler D; Trapani F; Arnhof H; Rumpel K; Botesteanu DA; Ettmayer P; Gerstberger T; Kofink C; Wunberg T; Zoephel A; Fu SC; Teh JL; Böttcher J; Pototschnig N; Schachinger F; Schipany K; Lieb S; Vellano CP; O'Connell JC; Mendes RL; Moll J; Petronczki M; Heffernan TP; Pearson M; McConnell DB; Kraut N
    Cancer Discov; 2021 Jan; 11(1):142-157. PubMed ID: 32816843
    [No Abstract]   [Full Text] [Related]  

  • 54. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
    Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR
    Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. D-1553: A novel KRAS
    Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
    Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
    Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
    Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
    Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
    Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adagrasib: a novel inhibitor for
    Guo MZ; Marrone KA; Spira A; Rosner S
    Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reflections on drug resistance to KRAS
    Han Z; Zhou D; Wang J; Jiang B; Liu X
    Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188677. PubMed ID: 35033622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.